IE stock · Healthcare sector · Medical Devices
M
Medtronic plc
MDT
NYSE81.46
USD
-2.08
(-2.49%)
Market Closed
28.77P/E
15Forward P/E
1.19P/E to S&P500
108.408BMarket CAP
- -Div Yield
Upcoming Earnings
25 May
Shares Short
5/15/23
10.7M
Short % of Float
0.80%
Short % of Shares Outs.
0.80%
% Held by Insiders
0.09%
% Held by Institutions
84.54%
Beta
0.72
PEG Ratio
15.51
52w. high/low
100.62/75.77
Avg. Daily Volume
5.99M
Return %
Stock
S&P 500
1 year
(16.91)
2.12
3 years
(15.63)
40.04
5 years
(6.41)
54.55
Scale: |
High
Low
56.97
28.33
44.94
24.06
46.66
30.80
43.33
30.18
44.79
35.67
58.85
41.16
75.66
53.33
79.50
55.54
89.27
71.03
89.72
69.35
100.15
76.41
115.94
81.66
122.15
72.13
135.89
98.38
114.31
75.77
92.02
76.02
Currency: USD
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Revenue per share
11.95
13.06
14.30
14.79
15.36
16.28
16.97
18.49
20.45
21.55
22.08
22.70
21.57
22.39
23.60
23.48
Earnings per share
1.97
1.94
2.80
2.87
3.43
3.40
3.06
2.44
2.51
2.92
2.29
3.44
3.57
2.68
3.75
2.85
FCF per share
2.02
2.58
2.91
3.24
3.03
3.90
4.42
4.17
3.07
3.03
4.15
2.69
4.38
4.48
3.64
4.50
Dividends per share
0.45
0.51
0.76
0.84
0.92
1.00
1.05
1.02
0.95
1.55
1.75
1.85
2.01
2.15
2.32
2.54
CAPEX per share
0.61
0.54
0.60
0.59
0.52
0.49
0.46
0.36
0.41
0.76
0.92
0.79
0.85
0.90
1.01
1.03
Book Value per sh.
9.71
10.32
11.62
13.58
15.15
16.79
18.63
17.75
37.76
37.76
37.07
37.67
37.36
37.73
38.31
39.52
Comm.Shares outs.
1,131
1,118
1,106
1,077
1,054
1,019
1,002
1,096
1,410
1,379
1,357
1,346
1,341
1,345
1,342
1,330
Avg. annual P/E ratio
23.7
18.0
13.9
12.9
11.6
15.1
20.6
30.4
31.9
27.8
38.4
28.7
28.6
45.3
25.2
29.4
P/E to S&P500
1.1
0.3
0.7
0.8
0.8
0.9
1.1
1.5
1.4
1.2
1.5
1.2
0.8
1.5
1.2
1.2
Avg. annual div. yield
1.0%
1.4%
2.0%
2.3%
2.3%
2.0%
1.7%
1.4%
1.2%
1.9%
2.0%
1.9%
2.0%
1.8%
2.5%
3.0%
Revenue (m)
13,515
14,599
15,817
15,933
16,184
16,590
17,005
20,261
28,833
29,710
29,953
30,557
28,913
30,117
31,686
31,227
Operating margin
21.3%
19.3%
27.6%
26.2%
29.0%
28.0%
24.0%
18.6%
18.4%
17.9%
22.2%
20.5%
16.6%
14.9%
18.2%
19.1%
Depreciation (m)
637
699
772
804
833
819
850
1,692
3,251
3,287
2,823
3,396
3,450
3,449
3,180
(489)
Net profit (m)
2,231
2,169
3,099
3,096
3,617
3,467
3,065
2,675
3,538
4,028
3,104
4,631
4,789
3,606
5,039
3,784
Income tax rate
22.7%
16.4%
21.9%
16.8%
17.6%
18.4%
17.3%
23.3%
18.4%
12.6%
45.5%
10.5%
(18.5)%
6.8%
8.3%
29.5%
Net profit margin
16.5%
14.9%
19.6%
19.4%
22.3%
20.9%
18.0%
13.2%
12.3%
13.6%
10.4%
15.2%
16.6%
12.0%
15.9%
12.1%
Working capital (m)
5,355
3,787
4,313
4,718
4,403
3,658
13,902
15,651
21,671
16,435
10,653
12,896
13,495
11,665
14,039
10,665
Long-term debt (m)
5,578
5,802
6,772
6,944
8,112
7,359
9,560
10,259
33,673
30,158
25,881
23,705
24,486
22,021
26,378
20,372
Equity (m)
10,977
11,536
12,851
14,629
15,968
17,113
18,671
19,443
53,230
52,063
50,294
50,720
50,091
50,737
51,428
52,551
ROIC
13.2%
12.6%
16.6%
15.1%
15.0%
13.9%
10.9%
8.9%
4.4%
5.0%
4.2%
6.9%
7.0%
5.2%
6.2%
5.4%
Return on capital
14.8%
12.7%
18.5%
14.9%
15.4%
14.0%
11.7%
9.9%
5.0%
5.3%
6.7%
6.9%
5.3%
4.9%
6.2%
6.6%
Return on equity
20.3%
18.8%
24.1%
21.2%
22.7%
20.3%
16.4%
13.8%
6.6%
7.7%
6.2%
9.1%
9.6%
7.1%
9.8%
7.2%
Plowback ratio
82.0%
74.7%
61.1%
70.7%
68.7%
(Infinity)%
69.6%
63.6%
50.0%
39.5%
41.0%
19.4%
42.1%
39.8%
14.0%
33.2%
Div.&Repurch./FCF
53.0%
59.2%
36.9%
50.7%
63.4%
59.6%
46.0%
51.8%
60.2%
107.3%
97.6%
117.9%
77.9%
59.1%
67.5%
92.0%
Capital Structure
25 May · 2023 | Q4
All numbers in millions
Total liabilities
$ 39,283
Total assets
$ 90,948
Long-term debt
$ 24,344
Cash and equiv.
$ 1,543
Goodwill
$ 41,425
Retained earnings
$ 30,392
Common stock
1,330
Enterprise Value
$ 131,209
Working Capital
Currency: USD, in millions
2020
2021
2022
Cash & Investments
10,948
10,817
10,573
Receivables
4,645
5,462
5,551
Inventory
4,229
4,313
4,616
Other
2,209
1,409
1,893
Current assets
22,031
22,548
23,059
Acc. Payable
1,996
2,106
2,276
Debt due
2,776
11
3,742
Other
5,594
6,392
6,376
Current liabilities
10,366
8,509
12,394
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
(1.45)%
0.64%
7.76%
Cash flow
22.37%
17.11%
6.88%
Earnings
(24.91)%
(1.61)%
5.91%
Dividends
8.39%
7.92%
14.81%
Book value
2.18%
0.90%
19.64%
Insider Trading
Type
Shares
Date
Oleary Denise M
Award
1,930
05/01/23
Oleary Denise M
InKind
169
05/02/23
Powell Kendall J
Award
1,930
05/01/23
Powell Kendall J
InKind
169
05/02/23
Lofton Kevin E
Award
1,930
05/01/23
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2021
6,507
7,647
7,775
8,188
30,117
2022
7,987
7,847
7,763
8,089
31,686
2023
7,371
7,585
7,727
8,544
31,227
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.36
0.36
0.94
1.01
2.68
2022
0.57
0.98
1.10
1.11
3.76
2023
0.70
0.32
0.92
0.89
2.83
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2021
0.58
0.58
0.58
0.58
2.32
2022
0.63
0.63
0.63
0.63
2.52
2023
0.68
0.68
0.68
- -
- -
Company Description
Sector:
Healthcare
Industry:
Medical Devices
CEO:
Mr. Geoffrey Straub Martha
Full-time employees:
95,000
City:
Dublin
Address:
20 On Hatch
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Recent News
· 21 Feb, 2023 · The Wall Street Journal
· 22 Nov, 2022 · The Wall Street Journal
· 7 Nov, 2022 · The Wall Street Journal
· 24 Oct, 2022 · The Wall Street Journal
· 24 Aug, 2021 · The Wall Street Journal
· 3 Jun, 2021 · The Wall Street Journal